{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T19:50:12Z","timestamp":1722023412851},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T00:00:00Z","timestamp":1531699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"St. Antonius Hospital Research Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,4,1]]},"DOI":"10.1093\/ehjqcco\/qcy030","type":"journal-article","created":{"date-parts":[[2018,7,14]],"date-time":"2018-07-14T10:58:49Z","timestamp":1531565929000},"page":"127-135","source":"Crossref","is-referenced-by-count":3,"title":["Economic evaluation of the use of non-vitamin K oral anticoagulants in patients with atrial fibrillation on antiplatelet therapy: a modelling analysis using the healthcare system in the Netherlands"],"prefix":"10.1093","volume":"5","author":[{"given":"Naoual","family":"Bennaghmouch","sequence":"first","affiliation":[{"name":"Department of Cardiology, St. Antonius Hospital, Koekoekslaan 1, CM Nieuwegein, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne J W M","family":"de Veer","sequence":"additional","affiliation":[{"name":"Department of Cardiology, St. Antonius Hospital, Koekoekslaan 1, CM Nieuwegein, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bakhtawar K","family":"Mahmoodi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, St. Antonius Hospital, Koekoekslaan 1, CM Nieuwegein, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mireia","family":"Jofre-Bonet","sequence":"additional","affiliation":[{"name":"Department of Economics, City University of London, Northampton Square, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory Y H","family":"Lip","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Sciences, University of Birmingham, City Hospital, Birmingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerstin","family":"Bode","sequence":"additional","affiliation":[{"name":"Heart Center, University of Leipzig, Str\u00fcmpellstra\u00dfe 39, Leipzig, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jurri\u00ebn M","family":"ten Berg","sequence":"additional","affiliation":[{"name":"Department of Cardiology, St. Antonius Hospital, Koekoekslaan 1, CM Nieuwegein, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,7,16]]},"reference":[{"key":"key\n\t\t\t\t2019032909594494400_qcy030-B1","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1001\/jama.2013.1556","article-title":"Association between bleeding events and in-hospital mortality after percutaneous coronary intervention","volume":"309","author":"Chhatriwalla","year":"2013","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019032909594494400_qcy030-B2","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1161\/CIRCULATIONAHA.112.114967","article-title":"Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study","volume":"126","author":"Lamberts","year":"2012","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019032909594494400_qcy030-B3","doi-asserted-by":"crossref","first-page":"672","DOI":"10.4244\/EIJV8I6A105","article-title":"Triple antithrombotic therapy following an acute coronary syndrome: prevalence, outcomes and prognostic utility of the HAS-BLED score","volume":"8","author":"Smith","year":"2012","journal-title":"EuroIntervention"},{"key":"key\n\t\t\t\t2019032909594494400_qcy030-B4","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMe0706859","article-title":"Intensifying platelet inhibition\u2013navigating between Scylla and Charybdis","volume":"357","author":"Bhatt","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019032909594494400_qcy030-B5","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.jacc.2015.02.051","article-title":"When is a double better than a triple? Stenting in patients with atrial fibrillation","volume":"65","author":"Bhatt","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t2019032909594494400_qcy030-B6","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t2019032909594494400_qcy030-B7","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1136\/bmj.325.7367.762","article-title":"ABC of antithrombotic therapy: an overview of antithrombotic therapy","volume":"325","author":"Blann","year":"2002","journal-title":"BMJ"},{"key":"key\n\t\t\t\t2019032909594494400_qcy030-B8","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019032909594494400_qcy030-B9","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019032909594494400_qcy030-B10","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019032909594494400_qcy030-B11","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019032909594494400_qcy030-B12","article-title":"ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: the Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO)","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t2019032909594494400_qcy030-B13","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1161\/CIRCULATIONAHA.117.028513","article-title":"The efficacy and safety of the use of non-vitamin-K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation and concomitant aspirin therapy: a meta-analysis of randomized trials","volume":"137","author":"Bennaghmouch","year":"2018","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019032909594494400_qcy030-B14","doi-asserted-by":"crossref","first-page":"20151.","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"key\n\t\t\t\t2019032909594494400_qcy030-B15","doi-asserted-by":"crossref","first-page":"g7647.","DOI":"10.1136\/bmj.g7647","article-title":"Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015: elaboration and explanation","volume":"349","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"key\n\t\t\t\t2019032909594494400_qcy030-B16","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1161\/CIRCULATIONAHA.112.115386","article-title":"Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomised Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial","volume":"127","author":"Dans","year":"2013","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019032909594494400_qcy030-B17","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/eurheartj\/eht445","article-title":"Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial","volume":"35","author":"Alexander","year":"2014","journal-title":"Our Heart J"},{"key":"key\n\t\t\t\t2019032909594494400_qcy030-B18","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ahj.2016.05.019","article-title":"Use of concomitant aspirin in patients with atrial fibrillation: findings from the ROCKET AF trial","volume":"179","author":"Shah","year":"2016","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t2019032909594494400_qcy030-B19","doi-asserted-by":"crossref","first-page":"e002587","DOI":"10.1161\/JAHA.115.002587","article-title":"concomitant use of single antiplatelet therapy with edoxaban of warfarin in patients with atrial fibrillation: analysis from the ENGAGE AF-TIMI 48 trial","volume":"5","author":"Xu","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"key\n\t\t\t\t2019032909594494400_qcy030-B20"},{"key":"key\n\t\t\t\t2019032909594494400_qcy030-B21","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1471-2261-10-57","article-title":"The dynamics of mortality in follow-up time after an acute myocardial infarction, lower extremity arterial disease and ischemic stroke","volume":"10","author":"Vaartjes","year":"2010","journal-title":"BMC Cardiovasc Disord"},{"key":"key\n\t\t\t\t2019032909594494400_qcy030-B22","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1161\/STROKEAHA.114.006016","article-title":"Intracranial hemorrhage mortality in atrial fibrillation patients treated with dabigatran or warfarin","volume":"45","author":"Alonso","year":"2014","journal-title":"Stroke"},{"key":"key\n\t\t\t\t2019032909594494400_qcy030-B23","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1161\/STROKEAHA.111.000748","article-title":"The iScore predicts functional outcome in Korean patients with ischemic stroke","volume":"44","author":"Park","year":"2013","journal-title":"Stroke"},{"key":"key\n\t\t\t\t2019032909594494400_qcy030-B24","volume-title":"Nieuwe Antistollingsmiddelen: Een Gedoseerde Introductie","year":"2012"},{"key":"key\n\t\t\t\t2019032909594494400_qcy030-B25"},{"key":"key\n\t\t\t\t2019032909594494400_qcy030-B26","year":"2011"},{"key":"key\n\t\t\t\t2019032909594494400_qcy030-B27","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/euhj.2000.2308","article-title":"Cost-effectiveness of HMG coenzyme reductase inhibitors: whom to treat?","volume":"22","author":"Van Hout","year":"2001","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t2019032909594494400_qcy030-B28","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s12471-013-0386-y","article-title":"Treatment costs of acute myocardial infarction in the Netherlands","volume":"21","author":"Soekhlal","year":"2013","journal-title":"Neth Heart J"},{"key":"key\n\t\t\t\t2019032909594494400_qcy030-B29","doi-asserted-by":"crossref","first-page":"d1672.","DOI":"10.1136\/bmj.d1672","article-title":"Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis","volume":"342","author":"Greving","year":"2011","journal-title":"BMJ"},{"key":"key\n\t\t\t\t2019032909594494400_qcy030-B30","first-page":"2911","article-title":"Haghfelt TH. Cost-effectiveness of clopidogrel vs. Aspirin treatment in high-risk acute coronary syndrome patients in Denmark (in Danish)","volume":"168","author":"Heeg","year":"2006","journal-title":"Ugeskr Laeger"},{"key":"key\n\t\t\t\t2019032909594494400_qcy030-B31","doi-asserted-by":"crossref","first-page":"21.","DOI":"10.1186\/1478-7547-8-21","article-title":"Lifetime health effects and medical costs of integrated stroke services\u2014a non-randomized controlled cluster-trial based life table approach","volume":"8","author":"Baeten","year":"2010","journal-title":"Cost Eff Resour Alloc"},{"key":"key\n\t\t\t\t2019032909594494400_qcy030-B32","doi-asserted-by":"crossref","first-page":"2.","DOI":"10.1186\/1478-7547-1-2","article-title":"Costs of stroke and stroke services: determinants of patient costs and a comparison of costs of regular care and care organised in stroke services","volume":"1","author":"Van Exel","year":"2003","journal-title":"Cost Eff Resour Alloc"},{"key":"key\n\t\t\t\t2019032909594494400_qcy030-B33","first-page":"788","article-title":"Costs of treating bleeding and perforated peptic ulcers in the Netherlands","volume":"31","author":"de Leest","year":"2004","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t2019032909594494400_qcy030-B34","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1161\/01.STR.0000016401.49688.2F","article-title":"Direct costs of modern treatment of aneurysmal subarachnoid hemorrhage in the first year after diagnosis","volume":"33","author":"Roos","year":"2002","journal-title":"Stroke"},{"key":"key\n\t\t\t\t2019032909594494400_qcy030-B35"},{"key":"key\n\t\t\t\t2019032909594494400_qcy030-B36","volume-title":"Guide to the Methods of Technology Appraisal","year":"2008"},{"key":"key\n\t\t\t\t2019032909594494400_qcy030-B37","author":"Zorginstituut","year":"2015"},{"key":"key\n\t\t\t\t2019032909594494400_qcy030-B38","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s40256-014-0092-1","article-title":"Cost effectiveness of new oral anticoagulants for stroke prevention in patients with atrial fibrillation in two different European healthcare settings","volume":"14","author":"Verhoef","year":"2014","journal-title":"Am J Cardiovasc Drugs"},{"key":"key\n\t\t\t\t2019032909594494400_qcy030-B39","doi-asserted-by":"crossref","first-page":"e103974.","DOI":"10.1371\/journal.pone.0103974","article-title":"Economic evaluation of apixaban for the prevention of stroke in non-valvular atrial fibrillation in the Netherlands","volume":"9","author":"Stevanovi\u0107","year":"2014","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t2019032909594494400_qcy030-B40","doi-asserted-by":"crossref","first-page":"160S","DOI":"10.1378\/chest.08-0670","article-title":"Pharmacology and management of the vitamin K antagonists: ACCP Evidence-Based Clinical Practice Guidelines","volume":"133","author":"Ansell","year":"2008","journal-title":"Chest"},{"key":"key\n\t\t\t\t2019032909594494400_qcy030-B41","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1160\/TH12-01-0027","article-title":"Home-monitoring of oral anticoagulation vs. dabigatran: an indirect comparison","volume":"108","author":"Alonso-Coello","year":"2012","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t2019032909594494400_qcy030-B42","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s12913-015-0934-9","article-title":"Cost-effectiveness analysis of dabigatran and anticoagulation monitoring strategies of vitamin K antagonist","volume":"15","author":"Carles","year":"2015","journal-title":"BMC Health Serv Res"},{"key":"key\n\t\t\t\t2019032909594494400_qcy030-B43","volume-title":"Conti","author":"Rena","year":"2014"},{"key":"key\n\t\t\t\t2019032909594494400_qcy030-B44"}],"container-title":["European Heart Journal - Quality of Care and Clinical Outcomes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ehjqcco\/article-pdf\/5\/2\/127\/28245660\/qcy030.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,29]],"date-time":"2019-03-29T13:59:58Z","timestamp":1553867998000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjqcco\/article\/5\/2\/127\/5054505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,16]]},"references-count":44,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,7,16]]},"published-print":{"date-parts":[[2019,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjqcco\/qcy030","relation":{},"ISSN":["2058-5225","2058-1742"],"issn-type":[{"value":"2058-5225","type":"print"},{"value":"2058-1742","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,4]]},"published":{"date-parts":[[2018,7,16]]}}}